Loading...
Market
Story
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Adding Caplyta to Portfolio
Jan 13, 2025, 03:57 PM
Johnson & Johnson has announced the acquisition of Intra-Cellular Therapies Inc. for approximately $14.6 billion, marking the largest biotech deal in over a year. The deal involves a cash payment of $132 per share, representing a 39% premium over Intra-Cellular's closing stock price on the previous Friday. The acquisition aims to bolster Johnson & Johnson's portfolio in the treatment of central nervous system disorders, including schizophrenia, through the addition of Intra-Cellular's drug Caplyta. The transaction is expected to be completed within the year. This move comes amidst a backdrop of increased M&A activity in the pharmaceutical sector, spurred by upcoming patent expirations and a potentially more favorable regulatory environment under the incoming Trump administration.
View original story
Similar markets
Vertex Pharmaceuticals • 25%
Biogen • 25%
Gilead Sciences • 25%
Other Biopharma Companies • 25%
No further acquisitions • 25%
Multiple companies • 25%
Another named biotech company • 25%
Stoke Therapeutics • 25%
Competitors gain market share • 25%
Competitors lose market share • 25%
New competitors emerge • 25%
No significant impact • 25%
Eli Lilly • 25%
GSK • 25%
Other • 25%
Johnson & Johnson • 25%
Top 10 • 25%
Outside Top 10 • 25%
Top 3 • 25%
Top 5 • 25%
Increase by less than 5% • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
No significant increase • 25%
Other • 25%
Moderna • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Other Outcomes • 25%
Acquisition Delayed • 25%
Acquisition Completed • 25%
Acquisition Abandoned • 25%
Other • 25%
Pfizer • 25%
GlaxoSmithKline • 25%
AstraZeneca • 25%
No official outcome by end of 2025 • 25%
Acquisition abandoned • 25%
Acquisition delayed • 25%
Acquisition completed • 25%
Other • 25%
J&J stock remains within 5% of current price • 25%
J&J stock falls by more than 5% • 25%
J&J stock rises by more than 5% • 25%